TScan Therapeutics/$TCRX
1D1W1MYTD1Y5YMAX
About TScan Therapeutics
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
- Ticker
- $TCRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 138
- Headquarters
- Waltham, United States
- Website
- www.tscan.com
TCRX Metrics
BasicAdvanced
$51M
-
-$1.74
1.07
-
Price and volume
Market cap
$51M
Beta
1.07
52-week high
$2.57
52-week low
$0.72
Average daily volume
408K
Financial strength
Current ratio
3.372
Quick ratio
3.235
Long term debt to equity
103.55
Total debt to equity
131.693
Interest coverage (TTM)
-42.50%
Profitability
EBITDA (TTM)
-115.66
Gross margin (TTM)
-1,242.06%
Net profit margin (TTM)
-1,655.35%
Operating margin (TTM)
-1,667.02%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-31.53%
Return on equity (TTM)
-95.80%
Valuation
Price to revenue (TTM)
7.151
Price to book
0.74
Price to tangible book (TTM)
0.74
Price to free cash flow (TTM)
-0.429
Free cash flow yield (TTM)
-232.93%
Free cash flow per share (TTM)
-1.747
Growth
Revenue change (TTM)
2.15%
Earnings per share change (TTM)
-27.94%
3-year revenue growth (CAGR)
-24.33%
3-year earnings per share growth (CAGR)
-13.98%
What the Analysts think about TCRX
Analyst ratings (Buy, Hold, Sell) for TScan Therapeutics stock.
TCRX Financial Performance
Revenues and expenses
TCRX Earnings Performance
Company profitability
TCRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.